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ABSTRACT
Apolipoprotein B (apoB) mRNA editing is a nuclear
event that minimally requires the RNA substrate,
APOBEC-1 and APOBEC-1 Complementation Factor
(ACF). The co-localization of these macro-molecules
within the nucleus and the modulation of hepatic
apoB mRNA editing activity have been described
following a variety of metabolic perturbations,
but the mechanism that regulates editosome
assembly is unknown. APOBEC-1 was effectively
co-immunoprecipitated with ACF from nuclear, but
not cytoplasmic extracts. Moreover, alkaline
phosphatase treatment of nuclear extracts reduced
the amount of APOBEC-1 co-immunoprecipitated
with ACF and inhibited in vitro editing activity.
Ethanol stimulated apoB mRNA editing was
associated with a 2- to 3-fold increase in ACF
phosphorylation relative to that in control primary
hepatocytes. Significantly, phosphorylated ACF
was restricted to nuclear extracts where it co-
sedimented with 27S editing competent complexes.
Two-dimensional phosphoamino acid analysis of
ACF immunopurified from hepatocyte nuclear
extracts demonstrated phosphorylation of serine
residues that was increased by ethanol treatment.
Inhibition of protein phosphatase I, but not PPIIA or
IIB, stimulated apoB mRNA editing activity coincid-
ent with enhanced ACF phosphorylation in vivo.
These data demonstrate that ACF is a metabolically
regulated phosphoprotein and suggest that this
post-translational modification increases hepatic
apoB mRNA editing activity by enhancing ACF
nuclear localization/retention, facilitating the
interaction of ACF with APOBEC-1 and thereby
increasing the probability of editosome assembly
and activity.
INTRODUCTION
ApoB mRNA editing involves the site-speciﬁc deamination of
cytidine 6666 to uridine within a glutamine codon (CAA)
thereby creating an in-frame translation stop codon (1).
Consequently, two apoB protein variants are expressed,
full-length apoB100 and the truncated protein apoB48,
both of which participate in lipid transport, but with markedly
different roles as atherogenic risk factors (1). Minimally,
apoB mRNA editing requires the cytidine deaminase
APOBEC-1 as a homodimer (2–5), APOBEC-1 Comple-
mentation Factor (ACF) (6–9) and the tripartite editing
motif within the mRNA substrate (10–12). ACF is the
mooring sequence-speciﬁc RNA binding protein that directs
site-speciﬁc editing (6–9,13).
Limited tissue expression of APOBEC-1 and apoB mRNA
restricts editing in humans to the small intestine (>85%
editing), but apoB mRNA editing also occurs in the liver of
several species (3,14–16). Hepatic editing is modulated by
fasting and refeeding in part due to an insulin-dependent
increase in APOBEC-1 expression (17). Hepatic editing is
also regulated independently of changes in APOBEC-1
expression levels by developmental, hormonal and nutritional
perturbations (17–23). The mechanism for this form of edit-
ing activity regulation has not been deﬁned, but involves the
nuclear trafﬁcking of editing factors (24–27).
ApoB mRNA editing occurs primarily on spliced and poly-
adenylated RNA in the nucleus (2,24,25,28–30). Despite this,
APOBEC-1 and ACF are distributed in both the cytoplasm
and nucleus (24,26,29–31). In nuclear extracts, APOBEC-1
and ACF co-sedimented in 27S, editing-competent com-
plexes, but as inactive 60S complexes in cytoplasmic extracts
(6,24). Under in vitro editing conditions, 60S complexes
reorganized to active 27S complexes on reporter RNAs
(6,24). Furthermore, localization studies demonstrated that
ACF and APOBEC-1 trafﬁck between the cytoplasm and
the nucleus (26,27). In support of trafﬁcking as a regulatory
mechanism, ethanol, insulin and thyroid hormone stimulation
of hepatocyte editing activity were associated with an an
increase in nuclear localization of ACF (24,29,32).
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(21,23,29), and withdrawal of the stimulus both reduced the
abundance of ACF in the nucleus and suppressed editing
activity (23,24). Ethanol induced editing is not dependent
on de novo protein or RNA synthesis (33) suggesting that
modulation of pre-existing editing factors is sufﬁcient to
support enhanced editing activity. These observations sub-
stantiated the possibility that cytoplasmic 60S complexes
may serve as a reservoir of editing factors necessary for
rapid assembly of nuclear 27S editosomes. Protein phos-
phorylation is one of the most common protein modiﬁcations
known and its importance in the regulation of protein activity
has been well documented (34). In fact phosphorylation has
been implicated as having a role in apoB mRNA editing
although its mechanism remains unclear (35).
We show that ACF was phosphorylated on one or more
serine residues, and that ethanol and insulin induction of
apoB mRNA editing was accompanied by phosphorylation
of ACF. PhosphoACF was only detected in the nucleus,
and was selectively recovered with active 27S editosomes.
Although ACF and APOBEC-1 are both present in the cyto-
plasm, APOBEC-1 co-immunoprecipitated with ACF only
from nuclear extracts. Recovery of ACF/APOBEC-1 com-
plexes and apoB mRNA editing activity were dependent on
protein phosphorylation. Protein phosphatase inhibitor studies
suggest that protein phosphatase 1 is involved in regulating
editing activity, ACF phosphorylation and ACF subcellular
distribution. The signiﬁcance of ACF phosphorylation for
ACF trafﬁcking to the nucleus, association with APOBEC-1
and assembly into 27S editosomes and the regulation of
editing efﬁciency is discussed.
MATERIALS AND METHODS
Animal care, primary hepatocyte isolation and
hepatoma cell culture
Male Sprague-Dawley rats (275–325 g BW/Charles River
Laboratories, Wilmington, MA) were housed under 12 h
light/dark cycles and fed normal rat chow (Purina, St.
Louis, MO) ad libitum and euthanized between 9 and
10 a.m. Primary hepatocytes were isolated (23) and plated
onto BIOCOAT type I collagen coated dishes (Becton
Dickinson Labware, Franklin Lakes, NJ) in Waymouth’s
752/1 media (Sigma Chemical Co., St Louis, MO) containing
0.1 nM porcine insulin (Sigma) for 12–16 h prior to the onset
of each experiment.
McArdle RH7777 cells (ATCC Manassas, VA) stably
expressing HA epitope-tagged APOBEC-1 (36) were treated
for 4 h with 0.9% ethanol and fractionated into nuclear
extracts (23).
In vivo phosphorylation of ACF
In vivo
32P labeling was performed by intraperitoneal injec-
tion of rats with 12.5 mCi of orthophosphoric acid
(10 mCi/ml
32PO4; NEN, Boston, MA) buffered with
50 mM HEPES, pH 7.0 and 150 mM NaCl. After 4 h, rats
were sacriﬁced and hepatic cytoplasmic and nuclear extracts
prepared. Primary hepatocyte cultures in 60 mm dishes were
incubated in phosphate-free Minimum Essential Eagle Media
(Sigma) containing 0.1 nM porcine insulin for 6 h and sub-
sequently in fresh media containing 10 nM insulin (equival-
ent to that seen in post-prandial serum) or 0.45–0.9%
ethanol (AAPER Alcohol and Chemical Co., Shelbyville,
KY) (23,29) plus 2.0 mCi orthophosphoric acid. Cultures
were labeled for 4 h prior to extract preparation.
Subcellular extract preparations
Livers were perfused in situ with 0.25 M sucrose, 50 mM
Tris, pH 7.0 and 5 mM MgCl2 and protease inhibitors
(Roche, Indianapolis, IN) (6,24). Cytoplasmic and nuclear
extracts (37) were supplemented with 10 mM NaF and frac-
tionated through glycerol gradients.
Cultured primary hepatocytes and hepatoma cell lines were
rinsed with 1· Tris-buffered saline (TBS; 10 mM Tris and
150 mM NaCl, pH 7.5) and scraped into TBS containing
proteinase/phosphatase inhibitors (Roche). Nuclear and cyto-
plasmic extracts were prepared using the NE-PER kit (Pierce,
Rockford, IL) supplemented with 10 mM NaF and proteinase
inhibitors.
Glycerol gradient fractionation
Preparative (35 ml) 10–50% glycerol gradients containing
10 mM NaF were loaded with 20 mg or 2 mg of cytoplasmic
or nuclear S100 extract respectively and sedimented at
100000· g for 10 h at 7 C. The distribution of 11S, 27S
and 60S complexes (fractions 3/4, 5/6 and 7/8) was determ-
ined by the sedimentation of bovine serum albumin (6S),
catalase (11S) and 60S spliceosomes (6,24). Gradient frac-
tions were treated with DNase I and RNaseT1 to ensure
the removal of DNA or RNA prior to the analysis of ACF
32P-labeling.
In vitro editing reactions and RNA binding assays
In vitro editing reactions and quantitative poisoned-primer
extension assays were carried out using 80 mg of extract
proteins as described previously (11,37). ApoB RNA binding
assays were performed by subjecting nuclear extract
(80 mg) to in vitro editosome assembly and ultraviolet
cross-linking (37).
Protein phosphatase inhibitor studies
Primary hepatocytes were treated for 6 h with cantharidin,
endothall or okadaic acid at concentrations encompassing
their respective in vivo IC50 values as described by the
manufacturer (Calbiochem, La Jolla, CA) and their suggested
references. The effects of the compounds on apoB mRNA
editing were evaluated by RT–PCR and poisoned-primer
extension analysis (38). The effect of 470 nM cantharidin
on ACF subcellular distribution was investigated by treating
primary hepatocyte cultures for 4 h followed by nuclear and
cytoplasmic extract preparation.
To evaluate the effect of phosphatase inhibition on ACF
phosphorylation, cultures were pre-incubated for 2 h with
470 nM cantharadin in phosphate-free Waymouth’s media
and subsequently supplemented with 0.5 mCi
32PO4 and
incubated for an additional 4 h. Cultures were harvested
and subcellular extracts prepared.
3300 Nucleic Acids Research, 2006, Vol. 34, No. 11Immunological techniques
Rabbit polyclonal peptide-speciﬁc antibodies were raised
against ACF N-terminal (NT) sequence (NHKSGDGLS-
GTQKE) and C-terminal (CT) sequence (HTLQTL-
GIPTEGGD) (24) and afﬁnity puriﬁed with the
corresponding peptides (Bethyl Laboratories, Inc., TX). For
immunoprecipitation analyses all radiolabeled extracts were
adjusted to 5 mM MgCl2 and digested with 100 U of
DNase I (Promega, Madison, WI), RNase T1 (Roche) and
RNase A (Sigma) for 1 h on ice to remove radiolabeled nuc-
leic acid. Where applicable, extracts were incubated over-
night with ACF CT antibody at 4 C and subsequently
reacted with Protein A-agarose (Oncogene Research Pro-
ducts, Boston, MA) pre-washed with 1· TBS/10 mM NaF.
The immuno-absorbed material was washed three times
with 1· TBS/10 mM NaF, three times with 1· TBS/1 M
NaCl (36) and ﬁnally three times with 1· TBS. Immuno-
absorbed material to be treated with alkaline phosphatase
was washed with 50 mM Tris, pH 8.4, 1 mM MgCl2, 0.1
mM ZnCl2, 25% glycerol and then incubated with 5 U
CIAP for 1 h at 30 C and then washed six times with 1·
TBS. ACF-antibody complexes were eluted with 3 M sodium
thiocyanate, acetone precipitated and analyzed by 10.5%
SDS–PAGE followed by autoradiography and/or western
blotting with ACF NT antibody. For ACF immunoprecipita-
tion from gradient fractions an equal volume of pooled gradi-
ent fractions from sedimentation zones of interest were
reacted with sub-saturating amounts of ACF CT antibody to
ensure that the recovery of phosphoACF was not simply a
reﬂection of ACF abundance in each zone.
Two-dimensional gel electrophoresis
Extracts isolated from hepatocytes were analyzed for ACF
charge isoforms using the Protean isoelectric focusing (IEF)
system (Bio-Rad Laboratories, Hercules, CA). Immobilized
pH gradient (IPG) strips (Bio-Rad Laboratories, pH range
3–9.3) were hydrated with 150 mg nuclear or 340 mg cyto-
plasmic extract in two-dimensional (2D) loading buffer
(7.5 M urea, 1.0 M thiourea, 1% CHAPS, 58 mM DTT and
0.2% biolytes) and electrophoresed to equilibrium.
After completion of IEF the IPG strip was equilibrated
in SDS buffer for 30 min and then in iodoacetamide buffer
for additional 30 min according to the manufacturer’s
recommendations. Proteins were resolved through a 10.5%
Criterion gel (Bio-Rad Laboratories), transferred to nitro-
cellulose and reacted with ACF NT antibody.
Two-dimensional phosphoamino acid analysis
ACF was immunopuriﬁed using the ACF CT antibody from
27S enriched nuclear extracts of
32P-labeled primary hepato-
cytes cultured in basal media (0.1 nM insulin) or in basal
media containing 0.9% ethanol. Immunoprecipitates were
resolved by SDS–PAGE, blotted onto PVDF membrane
(Bio-Rad, CA) and ACF was identiﬁed by autoradiography,
excised and acid hydrolyzed in 5.7 N HCl at 110 C for 1 h
(39). Lyophilized hydrolysates were spiked with unlabeled
phosphoserine, phosphothreonine and phosphotyrosine
(Sigma) and resolved on thin layer chromatography plates
(Merck, Germany) by 2D electrophoresis using an HTLE
7000 peptide mapping system (CBS Scientiﬁc Co. Del Mar,
CA) (39). The migration of the unlabeled standards and
ACF radiolabeled amino acid(s) were visualized by
ninhydrin staining and PhosphorImager Scanning densito-
metry, respectively.
RESULTS
The minimal, functional editosome is composed of ACF, a
homodimer of APOBEC-1 and the apoB RNA substrate
(40,41). ACF and APOBEC-1 are distributed in the cyto-
plasm and nucleus of editing competent cells where they
co-localize in macromolecular complexes of 60S and 27S,
respectively (6,24). However, apoB mRNA editing is only
associated with nuclear 27S complexes (24,29). Given that
endogenous levels of APOBEC-1 are below the detection
limits of currently available antibodies (36), the interaction
of ACF with APOBEC-1 in the nucleus and cytoplasm was
analyzed by co-immunoprecipitation from extracts
prepared from McArdle cells that stably express HA-tagged
APOBEC-1 (25,36). As anticipated, ACF and APOBEC-1
were abundant in both cytoplasmic and nuclear starting
material (Figure 1). However, APOBEC-1 was efﬁciently
co-immunoprecipitated with ACF only from nuclear extracts.
Given the selective recovery of APOBEC-1 with nuclear
ACF (Figure 1), we investigated whether the interaction
between ACF and APOBEC-1 in nuclear extracts was
mediated by post-translational modiﬁcations such as protein
phosphorylation. Treatment of nuclear extracts with alkaline
phosphatase (10 U CIAP) resulted in a 3-fold reduction in
HA-tagged APOBEC-1 recovered with immunoprecipitated
ACF (Figure 2A).
As an interaction between ACF and APOBEC-1 is critical
for editing activity (42) we investigated the effect of alkaline
phosphatase treatment on in vitro editing activity of hepato-
cyte extracts. ApoB mRNA editing activity in CIAP-treated
Figure 1. Hepatic APOBEC-1 co-immunopurifies with nuclear ACF. A
McArdle cell line overexpressing HA-tagged APOBEC-1 was treated with
0.9% ethanol for 4 h and fractionated into cytoplasm and nuclear extracts.
Nuclear (N) and cytoplasmic (C) extracts were western blotted with the ACF
NT (top left panel) or anti-HA antibody (bottom left panel). ACF CT antibody
immunoprecipitates of nuclear and cytoplasmic extracts were western blotted
with the ACF NT antibody (top right panel). The blots were stripped and re-
probed with HA antibody (APOBEC-1, bottom left and right panels). ACF,
position of ACF; HC, position of Ig heavy chain. The quality of the
fractionation was assessed by western blotting for marker proteins as shown
in Figure 6. Data shown are representative of three independent experiments.
Statistical significance was determined to be P < 0.01 by unpaired t-test
relative to nuclear co-IP.
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to control extracts (Figure 2B). The observed reduction in
editing activity could be attributed to the failure of ACF to
interact with APOBEC-1 or with the RNA substrate. In con-
trast to the interaction with APOBEC-1, CIAP treatment (1, 5
or 10 U) did not signiﬁcantly increase ultraviolet light cross-
linking of ACF to apoB mRNA (Figure 2C). These data sug-
gest that the reduction in editing activity in CIAP-treated
extracts was most probably the result of suppression of
interactions between ACF and APOBEC-1 rather than an
alteration in the binding afﬁnity of ACF to apoB mRNA.
ACF is a phosphoprotein
Previous studies using site-directed mutagenesis of
APOBEC-1 and overexpression of protein kinase Cq implic-
ated phosphorylation of APOBEC-1 as a mechanism for
activating apoB mRNA editing (35). Although our aforemen-
tioned data are consistent with this possibility, the low level
of endogenous APOBEC-1 expression has prohibited in vivo
validation of this ﬁnding. Furthermore, in vivo studies carried
out in our laboratory using exogenous rat APOBEC-1 were
unable to detect APOBEC-1 phosphorylation (data not
shown) and the phosphorylation sites suggested by the
authors are not conserved between rat and human (35).
To evaluate whether endogenous ACF is phosphorylated
in vivo, rats were radiolabeled for 4 h via an intraperitoneal
injection of orthophosphoric acid in HEPES-buffered saline.
Following extensive digestion of hepatic nuclear extracts
with DNase I and RNase T1 to remove radiolabeled nucleic
acids, ACF was immunoprecipitated with the CT antibody,
resolved by SDS–PAGE, transferred to nitrocellulose and
analyzed by autoradiography as well as immunoblotting
with ACF NT antibody (Figure 4A). A single band was detec-
ted by autoradiography that super-imposed with ACF-speciﬁc
immunoblot reactivity. Greater than 90% of the
32P-label was
removed by CIAP treatment (Figure 4B), consistent with the
post-translational phosphorylation of protein. Cytoplasmic
Figure 2. Phosphatase treatment inhibits apoB mRNA editing.
(A) Co-immunoprecipitation: The HA-tagged APOBEC-1 overexpressing
McArdle cell line was treated with ethanol for 4 h and fractionated. Nuclear
extracts were immunoprecipitated with ACF CT antibody and processed as
described in Figure 1. For CIAP treatment extracts were adjusted to 5 mM
MgCl2, 3 mM CaCl2, 0.1 mM ZnCl2 and 25% glycerol and then incubated
with 5 U CIAP for 1 h at 30 C. Control extracts were treated similarly but
lacked phosphatase. The ratios of APOBEC-1:ACF were determined by
scanning densitometry and quantitation using ImageJ Software. HC, position
of Ig heavy chain. (n ¼ 4, SD ±0.2). (B) In vitro editing activity: Liver
nuclear extract was treated with CIAP as described above. In vitro editing
activity was determined using the poisoned-primer extension assay. The
percent editing was quantified by PhoshorImager (Molecular Dynamics)
scanning densitometry. (n ¼ 4, SD ± 0.2, p < 0.01). (C) RNA binding: ACF
RNA binding activity was determined by ultraviolet light induced
cross-linking of liver nuclear extracts. Quantitation of relative amounts
of ACF bound was performed using PhoshorImager scanning densitometry.
(n ¼ 4, SD ± 0.2, p < 0.01).
Figure 3. Hepatic ACF is a phosphoprotein. (A) Hepatic ACF is
phosphorylated in vivo: ACF was immunopurified from radiolabeled 27S
containing glycerol gradient fractions (i.e. editosomes) and incubated with
100 U CIAP or buffer alone (control). Membranes were exposed to X-ray
film (autorad) and subsequently reacted with ACF NT antibody (western).
HC, position of Ig heavy chain. Data shown are representative of three
independent experiments. (B) Nuclear ACF contains more than one
phosphorylated residue. Rat liver nuclear extracts (150 mg), incubated with
or without 100 U CIAP were resolved by equilibrium 2D gel electrophoresis.
The applicable range of the gel is shown corresponding to pH 8.3–9.3. The
boxed area delineates the acidic isoform of ACF that was not observed
following CIAP treatment. Nuclear extract was run on the end of the second
dimension gel to verify the relative migration (Mr) of ACF and is delineated
by a vertical bar. Data shown are representative of two independent
experiments. (C) ACF is phosphorylated on serine residue(s): ACF was
immunoprecipitated from control or 0.9% ethanol-treated radiolabeled rat
hepatocytes and transferred to PVDF. The radiolabeled band corresponding to
ACF western blot reactivity was excised from the blot, acid hydrolyzed and
the products from control and ethanol-treated hepatocytes resolved in parallel
by 2D thin layer electrophoresis. The migration of phosphoamino acids was
determined from ninhydrin staining of known standards spiked into the
samples and is indicated and the thin layer plate was autoradiographed. Data
shown are representative of three independent experiments.
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acid sequence of rat ACF is predicted to contain 23 serine/
threonine and 7 tyrosine high probability sites of phos-
phorylation (http://www.cbs.dtu.dk/services.NetPhosK and
http://expasy.org/tools/scanprosite). To investigate the com-
plexity of physiologically relevant ACF phosphorylation
sites, liver extracts prepared from control rats were resolved
by equilibrium 2D gel electrophoresis and immunoblotted
with ACF NT antibody (24). The predicted isoelectric point
(pI) of ACF is 8.8 (http://www.scripps.edu/~cdputnam/
protcalc.html) and the covalent addition of phosphate would
be expected to cause an acidic shift of the pI (43). Nuclear
ACF was detected as two predominant charge isoforms
(Figure 3B). The major isoform migrated at pI 8.8 and is
likely unmodiﬁed ACF or ACF containing both acidic and
basic modiﬁcations. A second, less abundant, isoform
migrated with a pI of 8.3 and is consistent with phosphoryla-
tion of ACF. To verify that the observed charge heterogeneity
was due to protein phosphorylation, nuclear extracts were
treated with CIAP which resulted in an almost complete
loss of the acidic isoform (pI 8.3) and concomitant increase
in the pI 8.8 isoform (Figure 3B), which is consistent with
the removal of 2–3 phosphates (0.2–0.3 pH units per phos-
phate) (43). Cytoplasmic ACF migrated as a single isoform
at pI 8.8, which did not shift upon phosphatase treatment
(data not shown), further conﬁrming that cytoplasmic ACF
was not phosphorylated under our assay conditions.
To determine whether serine, threonine and/or tyrosine
residues were the target of phosphorylation, primary hepato-
cytes were labeled to high speciﬁc activity with 32PO4 and
ACF was immunoprecipitated from nuclear extracts. 2D
thin layer electrophoresis of acid hydrolyzed ACF demon-
strated that phosphorylation occurred on serine residues
(Figure 3C, left panel). Although this technique is not
intended for quantitation, it is interesting that the amount
of phosphoserine detected increased (1.5-fold) in ACF
immunopuriﬁed from an equivalent amount of nuclear extract
isolated from primary hepatocytes incubated with 0.9%
ethanol during the labeling period (Figure 3C, right panel).
The 1.5-fold change in phosphoserine abundance likely
represents a minimum as the radioactivity in partially hydro-
lyzed peptides (migrating along the ﬁrst dimension) suggest
greater
32P incorporation (see Materials and Methods).
These data suggest that threonine and tyrosine residues are
not phosphorylated in rat ACF or that their phosphorylation
exhibits a slow rate of turnover, preventing them from incorp-
orating
32P label during the experiment.
Phosphorylated ACF is only recovered with
nuclear editosomes
If phosphorylated ACF is relevant to editing activity, it
should be associated with nuclear 27S editosomes. To evalu-
ate this, cytoplasmic and nuclear extracts from radiolabeled
primary hepatocyte cultures were sedimented through
10–50% glycerol gradients. ACF was immunoprecipitated
with sub-saturating quantities of the ACF CT antibody from
pooled fractions corresponding to (i) 11S (pre-editosomal
ACF and APOBEC-1), (ii) the 27S editosome and (iii) 60S
and greater. The ACF immunoprecipitates were resolved by
SDS–PAGE, transferred to nitrocellulose, autoradiographed
and subjected to PhosphorImager scanning to detect and
quantify radiolabeled proteins prior to immunoblotting with
the ACF NT antibody. Consistent with prior analyses (24),
ACF was recovered by immunopuriﬁcation from all gradient
fractions (Figure 4A). Although ACF was widely distributed
in all nuclear fractions, phosphoACF was restricted to frac-
tions containing the 27S editosome. Editing activity, indicat-
ive of the assembly of APOBEC-1 with ACF has only been
observed in 27S gradient fractions (6). Considering data
presented in Figures 1, 2A and B, the selective recovery of
phosphorylated ACF in the nuclear 27S editosome fraction
is highly suggestive. Thus, a correlation linking phospho-
ACF to the physiologically relevant 27S editing complexes
can be made.
Phosphorylation of ACF is metabolically regulated
ApoB mRNA editing is regulated by a variety of hormonal
and dietary factors [reviewed in (44)]. To determine if ACF
phosphorylation is correlated with metabolic regulation of
editing rat primary hepatocytes were labeled with
32PO4 for
4 h in the presence of either 0.45% ethanol or 10 nM insulin.
A 3.5-fold increase of phosphoACF was associated with
nuclear 27S editosomes isolated from ethanol-treated
hepatocytes (Figure 4B). These data are consistent with
the increase in serine phosphorylation observed following
ethanol treatment (Figure 3C). Moreover, phosphoACF was
Figure 4. Phosphorylation of ACF is metabolically regulated and is localized
to nuclear active 27S editosomes: Cytoplasmic and nuclear extracts
were prepared from rat primary hepatocytes that had been labeled with
0.5 mCi
32PO4 for 4 h in the presence of (A) basal 0.1 nM insulin, (B) 0.45%
ethanol or (C) 10 nM insulin and fractionated through glycerol gradients.
ACF CT antibody immunoprecipitates were transferred to nitrocellulose and
exposed to X-ray film (autorad) and then reacted with ACF NT antibody
(western). Autoradiographs from the cytoplasmic fraction immunoprecipita-
tions represent exposures that were twice as long compared to those shown
for the nuclear fractions to ensure that phospho-ACF, if present, could be
detected. HC, position of Ig heavy chain. Data shown are representative of
three independent experiments.
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higher protein load compared with nuclear extracts onto the
gradients and a prolonged autoradiographic exposure
(Figure 4B).
To determine if enhanced ACF phosphorylation is a more
general mechanism associated with editing induction, we
investigated the effect of insulin treatment on primary hepato-
cytes. Insulin, like ethanol, stimulates apoB mRNA editing
(17,24) and the nuclear accumulation of ACF (24). Consistent
with data from ethanol-treated primary hepatocytes, addition
of 10 nM insulin during the 4 h labeling period resulted in a
2.5-fold increase in the recovery of phosphorylated ACF in
nuclear 27S editosomes (Figure 4C). No phosphoACF was
detected in any cytoplasmic fractions of insulin stimulated
hepatocytes. These data demonstrate that ACF phosphoryla-
tion is a general characteristic associated with modulation
of apoB mRNA editing activity.
ApoB mRNA editing and ACF phosphorylation can be
modulated by protein phosphatase inhibitors
If ACF phosphorylation is integral to the regulation of apoB
mRNA editing activity, and ACF must become dephos-
phorylated in order to trafﬁck to the cytoplasm, we reasoned
that inhibition of the appropriate protein phosphatase would
result in a nuclear accumulation of phosporylated ACF and
stimulate apoB mRNA editing. To evaluate this, hepatocytes
were treated with a series of protein phosphatase inhibitors
and editing activity determined. Protein phosphatase inhibit-
ors were selected such that we could identify or rule-out a
role for a speciﬁc class of protein phosphatases. Cantharidin
is a protein phosphatase inhibitor with markedly different
inhibitory concentrations for PP2A and PP1 (40 and 473
nM, respectively) (45,46). When tested at 470 nM, the IC50
for PP1, we detected a reproducible, but not statistically
signiﬁcant increase in editing (Figure 5A). Additional experi-
ments using 4.7 mM, a concentration anticipated to inhibit
>90% PP1 activity, editing increased from 66 to >90%
(Figure 5A). In addition, treatment of hepatocytes with both
cantharidin and ethanol simultaneously, conditions proposed
to stimulate both ACF nuclear localization and phosphoryla-
tion as well as to inhibit dephosphorylation resulted in the
largest stimulation of editing activity.
To further support the role of PP1 in editing regulation,
two additional protein phosphatase inhibitors, okadaic acid
(45) and endothall (47) were tested. Editing was enhanced
from 66 to >90% (P < 0.01) in hepatocytes treated with
okadaic acid at concentrations 10-times the IC50 for PP1
(Table 1). Similarly, treatment with endothall at a concentra-
tion 10-times the IC50 for PP1 stimulated editing to statistic-
ally signiﬁcant levels (P < 0.01) (Table 1).
Since calcium levels have been implicated in the regulation
of editing (18), we investigated the effect of inhibition of the
calcium-sensitive protein phosphatase 2B (PP2B) (48) on
editing. Treatment of hepatocytes with cyclosporin A (49)
and cypermethrin (50) did not affect signiﬁcantly apoB
mRNA editing (Table 1). In addition to ruling out PP2B,
these data also demonstrate that enhanced editing in the pres-
ence of protein phosphatase inhibitors is not a non-speciﬁc
effect owing to small molecule inhibitors; strengthening our
position that PP1 is involved in editing regulation.
In order to correlate the observed effects on editing with
changes in ACF phosphorylation, ACF was immunoprecipit-
ated from extracts isolated from hepatocytes treated with
increasing concentrations of cantharidin (Figure 5B). ACF
phosphorylation was increased in hepatocytes treated with
470 nM cantharidin. Maximal ACF phosphorylation was
observed when hepatocytes were treated with both ethanol
and cantharidin, reﬂecting the editing activity data described
in Figure 5A. Taken together, these data demonstrate that the
cellular effects of cantharidin that lead to enhanced editing
activity are associated with increased ACF phosphorylation.
Previous reports demonstrated accumulation of ACF in the
nucleus of hepatocytes treated with ethanol and insulin and
return of ACF to the cytoplasm upon removal of stimuli
(24). To evaluate the effect of PP1 inhibition on the nuclear
retention of ACF, hepatocytes were incubated with 470 nM
cantharidin for 4 h, fractionated into nuclear and cytoplasmic
Figure 5. Protein phosphatase I inhibitors modulate apoB mRNA editing and
ACF phosphorylation. (A) RNA Editing: rat primary hepatocytes were
incubated with concentrations of cantharidin ranging from 47 nM (IC50 of
PP2A) to 4.7 mM (10 times IC50 PP1) and 0.45% ethanol where indicated. In
vivo editing activity was determined on endogenous apoB mRNA using apoB
specific RT–PCR followed by poisoned-primer extension (38). *Statistical
significance was determined to be P < 0.01 by unpaired t-test relative to
DMSO control n > 5. (B) ACF phosphorylation and specific activity: in vivo
ACF
32P incorporation was determined by PhosphorImager scanning of ACF
immunoprecipitates prepared from rat hepatocytes treated with 470 nM
cantharidin. ACF-specific activity (relative to control hepatocytes) was
calculated as the ACF
32P density (PhosphorImager) divided by the recovery
of ACF determined from densitometric scanning of ACF western blots
(Image J). ACF immunopurified from control hepatocytes was arbitrarily
assigned a value of 1 (n ¼ 3). exp. 1 and exp. 2 denote independent
experiments 1 and 2.
3304 Nucleic Acids Research, 2006, Vol. 34, No. 11extracts, resolved by SDS–PAGE and immunoblotted for
ACF. Subsequently, the blots were re-probed for actin and
Histone H1 to verify cell fractionation quality and to serve
as normalization standards for protein loading (Figure 6).
The normalized relative abundance of nuclear to cytoplas-
mic ACF was 1:1 in control cells. Upon incubation with can-
tharidin a 5-fold increase in nuclear ACF was observed,
consistent with our hypothesis that inhibition of ACF dephos-
phorylation prevents its nuclear export.
DISCUSSION
Hepatic apoB mRNA editing is a regulated, nuclear process
that requires the assembly of multi-protein editosomes.
Reconstitution assays have identiﬁed the essential protein
factors as the cytidine deaminase APOBEC-1 and the auxili-
ary factor ACF. Data presented in this report demonstrate that
ACF is a phosphoprotein and that phosphoACF is restricted
to nuclear 27S editosomes. ACF was phosphorylated on
one or more serine residues under basal media conditions
and the proportion of total cellular ACF that became phos-
phorylated increased upon ethanol or insulin treatment, stim-
uli both known to enhance editing activity. This suggests that
ACF phosphorylation is metabolically regulated and a part of
the mechanism for activating apoB mRNA editing regardless
of whether APOBEC-1 expression is increased [insulin
treatment, (17,22)] or not [ethanol treatment, (21)].
Recombinant APOBEC-1 and ACF puriﬁed from
Escherichia coli, baculovirus or prepared from in vitro
translation extracts can edit apoB RNA in vitro suggesting
that phosphorylation is not essential for editosome assembly
and editing activity. However, we argue that the efﬁciency of
recombinant APOBEC-1 alone with recombinant ACF is
entirely dependent on input protein concentration and the
reaction has a very poor catalytic turnover, capable of only
attomolar RNA substrate editing per hour (3,31,51). This is
in sharp contrast to the highly efﬁcient endogenous hepatic
or intestinal cell editing activity. In fact, editing activity
in vivo is regulated in a species- and tissue-speciﬁc manner,
and inducible during development and in response to meta-
bolic and hormonal perturbations (14,16) [and reviewed in
(1)]. In this context, our data suggested that phosphorylation
of ACF optimized and/or stabilized the functional interaction
with APOBEC-1 in the nucleus leading to efﬁcient editing
activity. This mechanism explained how apoB mRNA editing
activity can be activated metabolically or during development
using pre-existing editing factors.
Under basal conditions, inhibition of PP1 activity resulted
in the nuclear retention and increased recovery of phos-
phoACF and increased apoB mRNA editing activity, suggest-
ing that ACF phosphorylation/dephosphorylation contributes
to the modulation of editosome assembly and editing activity.
Given that not all nuclear ACF is phosphorylated (Figures 3B
and 4) and that not all ACF is assembled in 27S editosomes
[Figure 4 and (12,24)] our data suggest that at any given time
not all of the cellular ACF is involved in editing. This implies
that there is a pool of ACF that can be used to rapidly modu-
late editosome assembly upon metabolic or hormonal stimuli
or that ACF has additional roles in the cell.
In addition to editosome structure and function, ACF plays
an important role in the cellular regulation of apoB mRNA
editing through its trafﬁcking activity between the cytoplasm
Table 1. Protein phosphatase I inhibitors modulate apoB mRNA editing. Rat
primary hepatocytes were treated with the indicated concentrations of protein
phosphatase inhibitors for 6 h. Editing activity was determined on the
endogenous apoB mRNA using apoB specific RT-PCR followed by poisoned-
primer extension (38). The mean, standard deviation (STD) and number of
replicates (n) are indicated for each determination. *Statistical significance
was determined to be P < 0.01 by unpaired t-test relative to DMSO control
when n>3.
Mean STD n
Okadaic acid
a
Primary hepatocytes 66.3 2.8 5
DMSO 68.5 4.2 5
1 nM 71.2 2.0 3
10 nM 73.0 3.1 3
100 nM 91.4* 3.4 4
Endothall
b
Primary hepatocytes 65.2 1.9 4
DMSO 69.8 3.0 4
100 nM 66.5 4.1 4
500 nM 65.2 6.0 4
5 mM 63.7 2.8 3
50 mM 83* 3.0 4
Cyclosporin A
c
Primary hepatocytes 66.2 1.3 6
DMSO 66.4 4.2 6
5 nM 66.2 4.2 4
50 nM 66.8 6.6 5
500 nM 71.8 3.8 4
Cypermethrin
d
Primary hepatocytes 64.9   2
DMSO 63.1   2
50 pM 69.4   2
5 nM 65.9   2
aIC50; PP1 ¼ 10–15 nM, PP2A ¼ 0.1 nM
bIC50; PP1 ¼ 5 mM, PP2A ¼ 90 nM
cIC50; PP2B ¼ nM, range
dIC50; PP2B ¼ 40 pM
Figure 6. Inhibition of PP1 results in nuclear accumulation of ACF: Rat
primary hepatocytes were incubated with 470 nM cantharidin for 4 h and
fractionated. Nuclear (N) and cytoplasmic (C) extracts were western blotted
for ACF and subsequently for actin and H1 histone. N/C ratio were
determined by normalizing N ACF to the corresponding recovery of H1
histone and C ACF was normalized to corresponding recovery of actin for
each sample using scanning densitometry of non-saturated immunoblots.
Data shown are representative of four independent experiments (SD ±2.1-fold
for cantharidin).
Nucleic Acids Research, 2006, Vol. 34, No. 11 3305and the nucleus (24–27,30). Although the site of apoB mRNA
editing is within the cell nucleus (2,29) and takes place during
or immediately after pre-mRNA splicing (2,28,38),
APOBEC-1 and ACF are distributed in both the nucleus
and cytoplasm (9,24,26,27,30). The data presented here sug-
gest that nuclear retention/import of ACF was increased in
ethanol or insulin treated hepatocytes through ACF phos-
phorylation. The mechanism for regulating APOBEC-1 and
ACF trafﬁcking are unknown, and the dependence of each
protein’s trafﬁcking on ACF–APOBEC-1 complex formation
is controversial (25–27,30). Data from our laboratory suggest
that APOBEC-1 has strong cytoplasmic retention signals, and
that its nuclear import is mediated by interactions with ACF
(25,30). We report that ACF and APOBEC-1 are present in
both the cytoplasm and nucleus of editing competent cells,
but that they only co-immunopurify from nuclear extracts.
Our data suggest that nuclear retention/import of ACF is
increased in ethanol or insulin treated hepatocytes through
modulation of ACF phosphorylation state. We propose a
model in which phosphorylation of ACF results in its nuclear
accumulation and enhances or stabilizes APOBEC-1 nuclear
retention and ACF binding, leading to increased editing activ-
ity. In support of this model, phosphatase treatment of cell
extracts was associated with reduced co-immunoprecipitation
of APOBEC-1 with ACF and reduced editing activity.
A small proportion of nuclear ACF was phosphorylated in
non-stimulated hepatocytes (0.1 nM insulin) (Figures. 3B and
C) which increased several-fold upon insulin and ethanol
stimulation (Figures 3B and C). These data suggested that a
low level turnover of ACF phosphorylation maybe required
to maintain basal apoB mRNA editing activity. Signiﬁcantly,
PP1 inhibition stimulated editing activity even under basal
media conditions. The turnover of editing complexes has
been suggested from studies that demonstrated nucleocyto-
plasmic shuttling of ACF and APOBEC-1 (26,27,30,36)
and from in vitro studies of editosome assembly (12). Addi-
tion of ethanol (or its catabolite, acetaldehyde) or chemicals
affecting protein kinases and phosphatases to nuclear extracts
did not affect in vitro editing activity or ACF phosphorylation
(data not shown). These data indicate that intact cell signal
transduction cascades are required for the regulation of
ACF phosphorylation and apoB mRNA editing. The identi-
ﬁcation of PP1 as a candidate phosphatase involved in regu-
lating phosphate turnover on ACF is relevant, as high levels
of PP1 are present in rat hepatocyte nuclei (52) of which 90%
was associated with chromatin (53). Nuclear ACF is also
associated with chromatin (24) placing it theoretically within
the general domain of nuclear PP1. The ability of phos-
phoACF to serve as substrate for PP1 remains to be formally
addressed.
The lack of labeled ACF in the cytoplasm also suggests
that ACF is dephosphorylated prior to or during nuclear
export. These data suggest an interesting hypothesis: if phos-
phorylation of ACF is restricted to the nucleus and associated
with enhanced editing activity, then dephosphorylation of
ACF might regulate its nuclear export. Given that ACF
binds to both unedited and edited apoB mRNA (6) and that
dephosphorylated ACF binds to apoB RNA. ACF is likely
to remain bound to apoB mRNA and co-export to the
cytoplasm following apoB mRNA editing and ACF
dephosphorylation. In this scenario, the regulation of ACF
dephosphorylation would modulate apoB mRNA export to
the cytoplasm in addition to protecting edited apoB mRNA
from nonsense mediated decay (NMD) (31).
Under basal conditions, 2D gel electrophoresis analyses
suggested that ACF contained 2–3 phosphates. 2D phos-
phoamino acid analyses indicated serines were the residues
phosphorylated following metabolic stimulation. ACF phos-
phorylation and whether these sites are the same as the
‘basal’ phosphorylation sites or are additional sites of phos-
phorylation remains to be determined. Although parallels
were observed when comparing ethanol with insulin editing
induction (i.e. ACF accumulation in the nucleus and ACF
hyperphosphorylation), we cannot assume that the same
sites of ACF phosphorylation are involved or that the phos-
phorylation state of additional editing factors is not affected.
In fact, previous studies involving alanine and aspartic acid
site-speciﬁc mutagenesis of predicted serine phosphorylation
sites suggested that APOBEC-1 may have two sites of phos-
phorylation which had opposing effects of editing activity
(35). APOBEC-1 has never been validated as a phosphopro-
tein through metabolic labeling studies similar to those repor-
ted here because the expression of endogenous APOBEC-1 is
prohibitively low. We evaluated phosphorylation of
APOBEC-1 overexpressed in a stable McArdle cell line
under basal and ethanol stimulated conditions and found no
evidence for radiolabeling during a 4 h incubation period
(data not shown). If APOBEC-1 is a phosphoprotein, the
sites of phosphorylation may not be subjected to acute regu-
lation and in fact Ser47 and Ser72, which were proposed to be
phosphorylated in human APOBEC-1, are not conserved in
rat APOBEC-1. The expression level of, and availability of
high titre antibodies against, two APOBEC-1 homologs
namely activation induced deaminase (AID) and APOBEC-
3G have made equivalent studies possible and both proteins
were identiﬁed as phosphoproteins (54,55). Consequently,
phosphorylation of APOBEC-1 and its role in regulating edit-
ing activity remains a formal possibility.
In conclusion, regulation of hepatic apoB mRNA editing
by ethanol and insulin promotes serine phosphorylation of
ACF and its localization to active nuclear 27S editosomes.
The data support a role for the metabolic regulation of
ACF phosphorylation that promotes its interaction with
APOBEC-1, in editosome assembly, as well as ACF nuclear
retention/import. Thus, phosphorylation of ACF adds a new
level of understanding of the control mechanisms cells use
to modulate apoB mRNA editing in the context of current
models of editosome composition and assembly.
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